Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...